x
Filter:
Filters applied
- CJCA - COVID-19
- Case ReportsRemove Case Reports filter
- LetterRemove Letter filter
Publication Date
Please choose a date range between 2020 and 2021.
Author
- Beigel, Roy2
- Fardman, Alexander2
- Matetzky, Shlomi2
- Oren, Daniel2
- Araújo, Claudio Gil Soares de1
- Ascenti, Giorgio1
- Aung, May Kyawt1
- Berenguer Jofresa, Alberto1
- Berkovitch, Anat1
- Bibas, Lior1
- Blandino, Alfredo1
- Bombardini, Tonino1
- Booz, Christian1
- Burns, Karen1
- Caplice, Noel M1
- Cardinal, Mikhail-Paul1
- Carerj, Maria Ludovica1
- Cattafi, Antonino1
- Cavallé-Garrido, Tiscar1
- Chen, Chen1
- Chen, Yan1
- Chen, Yaqin1
- Chua, Terrance Siang Jin1
- Cicero, Giuseppe1
- Conceicao, Edwin Philip1
19 Results
- Case Report
Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction?
Canadian Journal of CardiologyVol. 37Issue 10p1665–1667Published online: June 8, 2021- Tommaso D'Angelo
- Antonino Cattafi
- Maria Ludovica Carerj
- Christian Booz
- Giorgio Ascenti
- Giuseppe Cicero
- and others
Cited in Scopus: 41Vaccination plays an important role in the fight against SARS-CoV-2 to minimie the spread of coronavirus disease 2019 (COVID-19) and its life-threatening complications. Myocarditis has been reported as a possible and rare adverse consequence of different vaccines, and its clinical presentation can range from influenza-like symptoms to acute heart failure. We report a case of a 30-year-old man who presented progressive dyspnea and constrictive retrosternal pain after receiving SARS-CoV-2 vaccine. - Letters to the Editor
A Multiprofessional Face-to-Face and Remote Real-Time Hybrid Mode of Exercise-Based Cardiac Rehabilitation: An Innovative Proposal During the COVID-19 Pandemic
Canadian Journal of CardiologyVol. 37Issue 5p810.e1–810.e2Published online: January 12, 2021- Claudio Gil Soares de Araújo
- Christina Grüne De Souza e Silva
Cited in Scopus: 2Exercise-based cardiac rehabilitation is largely recognized as a cost-effective therapeutic strategy for several clinical conditions and formally recommended and endorsed by a number of institutional guidelines.1 Since 1994, in our medically supervised exercise program, more than 2500 patients have completed over 450,000 patient-hours in exercise sessions. However, during the COVID-19 pandemic, as happened worldwide, our on-site exercise sessions were suspended, and we had to quickly implement alternative options of home-based programs, using recent advances in telecommunications and health-monitoring technology. - Letters to the Editor
Reply to Čulić et al—COVID-19 Pandemic and Possible Rebound Phenomenon in Incidence of Acute Myocardial Infarction
Canadian Journal of CardiologyVol. 37Issue 8p1295Published online: December 14, 2020- Alexander Fardman
- Daniel Oren
- Roy Beigel
- Shlomi Matetzky
Cited in Scopus: 0We agree with Čulić et al1 regarding to the fact that the observed ST-segment elevation myocardial infarction (STEMI) hospitalisation rebound phenomenon is not entirely unexpected. Nonetheless, our report2 is indeed the first description of this worrisome trend. Israel saw its first confirmed COVID-19 patient on February 21. The first documented in-state transmission of the virus subsequently occurred on February 22. New government regulations calling for social distancing; limiting gatherings; and restrictions on public transportation, schools, universities, and businesses were announced on March 10. - Case Report
Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19
Canadian Journal of CardiologyVol. 37Issue 6p938.e3–938.e6Published online: October 23, 2020- Guillem Llopis Gisbert
- Verónica Vidal Urrutia
- Miguel A. Moruno Benita
- Ana Payá Chaume
- Alberto Berenguer Jofresa
- Andrés M. Cubillos Arango
- and others
Cited in Scopus: 6Patients with COVID-19 may present a hypercoagulable state, with an important impact on morbidity and mortality. Because of this situation pulmonary embolism is a frequent complication during the course of infection. We present the case of a patient recently discharged, after admission with confirmed COVID-19, who developed a pulmonary embolism and thrombosis of a biological mitral valve prosthesis, producing valve obstruction and stenosis. After 15 days of anticoagulant treatment, resolution of the thrombus and normalisation of prosthetic valve function was observed. - Letters to the Editor
Post COVID-19 Acute Myocardial Infarction Rebound
Canadian Journal of CardiologyVol. 36Issue 11p1832.e15–1832.e16Published online: August 27, 2020- Alexander Fardman
- Daniel Oren
- Anat Berkovitch
- Amit Segev
- Yuval Levy
- Roy Beigel
- and others
Cited in Scopus: 16As the first wave of COVID-19 came to a relative trough during May 2020 in parts of Europe and some states in the United States, for example Vermont, New York, and New Jersey, we are now beginning to observe a resurgence in acute myocardial infarction (AMI) admissions in Israel.1 - Letters to the Editor
The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients
Canadian Journal of CardiologyVol. 36Issue 10p1691.e3Published online: July 23, 2020- Shubham Soni
- Jason R.B. Dyck
Cited in Scopus: 5Recent evidence has shown that inflammation is a potential contributor to the progression and exacerbation of COVID-19.1 Indeed, SARS-CoV-2 often induces a robust immune response and releases cytokines, which might contribute to multiorgan dysfunction and mortality.1 Growing evidence suggests that COVID-19 is not solely a respiratory illness, and that the infection can directly or indirectly infect organs or vascular endothelial cells causing endotheliitis. Because of the urgent need for additional therapies and because COVID-19 disproportionately affects individuals with cardiovascular/cardiometabolic comorbidities, herein we discuss the rationale for using the antidiabetic sodium-glucose cotransporter 2 (SGLT2) inhibitors, namely dapagliflozin and empagliflozin, as a unique approach to potentially treat severe COVID-19 symptoms. - Case Report
Biventricular Thrombi Associated With Myocardial Infarction in a Patient With COVID-19
Canadian Journal of CardiologyVol. 36Issue 8p1326.e9–1326.e11Published online: June 26, 2020- Marwa Soltani
- Samer Mansour
Cited in Scopus: 6A wide spectrum of cardiovascular manifestations has been documented in patients suffering from coronavirus disease-2019 (COVID-19). Usually associated with a poor prognoses, these manifestations include thromboembolic events, acute coronary syndrome, heart failure, and cardiogenic shock. We describe a patient with COVID-19 who presented with subacute myocardial infarction, biventricular thrombi, and bilateral pulmonary emboli. Biventricular thrombi are rare, and their presence raises concern for an underlying prothrombotic condition. - Letter to the Editor
Cardiovascular Collateral Damages at the Time of COVID-19
Canadian Journal of CardiologyVol. 36Issue 8p1327.e7Published online: June 22, 2020- Frédéric Jacques
- Pierre Voisine
- Louis Perrault
Cited in Scopus: 1On March 13th, 2020, the Québec provincial government announced an extended lockdown over all sectors of the economy to face the COVID-19 pandemic.1 Supportive programs were instituted to insure implementation of effective social-distancing measures.2 Hospitals were asked to postpone elective and semielective procedures to spare personal protective equipment.3 The general population respected the request for confinement and stayed home. - Case Report
First Documentation of Persistent SARS-Cov-2 Infection Presenting With Late Acute Severe Myocarditis
Canadian Journal of CardiologyVol. 36Issue 8p1326.e5–1326.e7Published online: June 6, 2020- Anna Giulia Pavon
- David Meier
- Daryoush Samim
- David C. Rotzinger
- Stephane Fournier
- Patrick Marquis
- and others
Cited in Scopus: 13A 64-year-old man presented with severe myocarditis 6 weeks after an initial almost asymptomatic severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) infection. He was found to have a persistent positive swab. Mechanisms explaining myocardial injury in patients with COVID-19 remains unclear, but this case suggests that severe acute myocarditis can develop in the late phase of COVID-19 infection, even after a symptom-free interval. - Letter to the Editor
Strategic Cardiac Catheterization Lab Staffing in the Era of COVID-19: The Pod Initiative
Canadian Journal of CardiologyVol. 36Issue 8p1327.e5–1327.e6Published online: June 3, 2020- Kerrin M. Green
- Sohrab R. Lutchmedial
Cited in Scopus: 0The COVID-19 pandemic affected cardiovascular programs across Canada, with multiple professional organizations recommending deferral of all elective and semielective procedures to reduce exposures in the hospital setting and to save critical care capacity. Few recommendations directly addressed health care unit integrity. - Letter to the Editor
Surveillance for COVID-19 in Cardiac Inpatients: Containing COVID-19 in a Specialized Cardiac Centre
Canadian Journal of CardiologyVol. 36Issue 8p1327.e3–1327.e4Published online: May 27, 2020- Liang En Wee
- Wen Ruan
- Xiang Ying Jean Sim
- Kym Ng
- Poh Choo Phoon
- Edwin Philip Conceicao
- and others
Cited in Scopus: 3We read with interest the article by Cosentino et al., who described a triage pathway for patients with acute coronary syndrome (ACS) during a COVID-19 outbreak.1 However, although COVID-19 might manifest as ACS, other cardiac complications can also be associated with SARS-CoV-2 infection2; for instance, respiratory viruses can cause heart failure or myocarditis. Because a small percentage might be presymptomatic,3 this makes detection even more challenging. Some form of risk stratification is necessary to prioritize patients for COVID-19 testing. - Letter to the Editor
Family Engagement in the Cardiovascular Intensive Care Unit in the COVID-19 Era
Canadian Journal of CardiologyVol. 36Issue 8p1327.e1–1327.e2Published online: May 25, 2020- Michael Goldfarb
- Lior Bibas
- Karen Burns
Cited in Scopus: 6The COVID-19 pandemic has caused an abrupt shift in the way care is delivered in cardiovascular intensive care units (CICUs). One example of this drastic change has been the limitations placed on family visitation. In many hospitals across Canada and beyond, a strict "no visitor" policy has been implemented. Governments and hospital administrators have instituted this policy to prevent the spread of infection and preserve protective equipment. However, physical distancing may lead to social isolation and emotional distress for both patients and their families. - Letter to the Editor
Late STEMI and NSTEMI Patients’ Emergency Calling in COVID-19 Outbreak
Canadian Journal of CardiologyVol. 36Issue 7p1161.e7–1161.e8Published online: May 10, 2020- Daniela Trabattoni
- Piero Montorsi
- Luca Merlino
Cited in Scopus: 27The highly contagious coronavirus that causes COVID-19 disease is affecting daily clinical practice. The anticipated fast growth in cases has led to development of a regional restructuring model to preserve time-sensitive pathologies in northern Italy. On this way, the Lombardy Region Government built up a big hub-and-spoke model to converge treatment of acute coronary syndrome (ACS) in 13 dedicated centres active 24/7 in the region, implementing availability of intensive care unit beds in general hospitals converted to COVID-19 treatment. - Letter to the Editor
COVID-19—Where Have All the STEMIs Gone?
Canadian Journal of CardiologyVol. 36Issue 7p1161.e9–1161.e10Published online: May 3, 2020- Richard Tanner
- Paul MacDaragh Ryan
- Noel M. Caplice
Cited in Scopus: 12The COVID-19 pandemic has required acute and long-term services to accommodate surges in hospital admissions. Cardiovascular care has experienced challenges to primary percutaneous coronary intervention (PPCI) from safety (personal protective equipment), staffing (health care worker infection rates), and patient welfare perspectives. Recently, an approximately 40% reduction in ST-segment-elevation myocardial infarction (STEMI) presentations for PPCI has been reported during the COVID-19 crisis.1 Reduced STEMI admissions could relate to altered patient behaviour, disrupted care pathways, or altered cardiovascular risk factors pertaining to partial or complete lockdown conditions during the pandemic (Fig. 1). - Letter to the Editor
Considerations for Scaling Down Fetal Echocardiography During the COVID-19 Pandemic
Canadian Journal of CardiologyVol. 36Issue 6p969.e5–969.e6Published online: April 21, 2020- Mikhail-Paul Cardinal
- Thomas G. Poder
- Marie-Eve Roy-Lacroix
- Tiscar Cavallé-Garrido
- Laurence Vaujois
- Frederic Dallaire
- and others
Cited in Scopus: 3In the context of the COVID-19 pandemic, institutions performing fetal echocardiography (FE) are weighing the risks and benefits of reducing the number of FE to free up resources and limit nonessential visits to hospitals and clinics. These decisions must be made rapidly, often without a solid knowledge base. As of the first week of April 2020, strategies adopted by Canadian institutions varied considerably, with some significantly scaling down the rate of FE and others maintaining the pace as before the pandemic. - Letter to the Editor
What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?
Canadian Journal of CardiologyVol. 36Issue 6p969.e3Published online: April 8, 2020- Thadathilankal-Jess John
- Kiran John
Cited in Scopus: 2The recent publication by Bombardini et al. suggests an important role of the renin angiotensin aldosterone system (RAAS) in the development of acute respiratory distress syndrome (ARDS) in patients with underlying infection with the novel coronavirus, SARS-CoV-2.1 - Letter to the Editor
Rapid Scholarly Dissemination and Cardiovascular Community Engagement to Combat the Infodemic of the COVID-19 Pandemic
Canadian Journal of CardiologyVol. 36Issue 6p969.e1–969.e2Published online: April 4, 2020- Dominique Vervoort
- Xiya Ma
- Jessica G.Y. Luc
- Shelley Zieroth
Cited in Scopus: 12While the body of literature on the novel coronavirus disease 2019 (COVID-19)-related cardiac complications rapidly expands alongside the exponential surge of confirmed cases,1 print and social media pose significant challenges and opportunities in propagating an infodemic during the COVID-19 pandemic. - Case Report
Characteristic Electrocardiographic Manifestations in Patients With COVID-19
Canadian Journal of CardiologyVol. 36Issue 6p966.e1–966.e4Published online: March 29, 2020- Jia He
- Bo Wu
- Yaqin Chen
- Jianjun Tang
- Qiming Liu
- Shenghua Zhou
- and others
Cited in Scopus: 55Cardiac involvement has been reported in patients with COVID-19, which may be reflected by electrocardiographic (ECG) changes. Two COVID-19 cases in our report exhibited different ECG manifestations as the disease caused deterioration. The first case presented temporary SIQIIITIII morphology followed by reversible nearly complete atrioventricular block, and the second demonstrated ST-segment elevation accompanied by multifocal ventricular tachycardia. The underlying mechanisms of these ECG abnormalities in the severe stage of COVID-19 may be attributed to hypoxia and inflammatory damage incurred by the virus. - Letters to the Editor
Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19
Canadian Journal of CardiologyVol. 36Issue 5p784.e1–784.e2Published online: March 28, 2020- Tonino Bombardini
- Eugenio Picano
Cited in Scopus: 36Pre-existent cardiovascular disease is a recognized risk factor for COVID-19 infection.1 COVID-19 spike protein uses the angiotensin-converting enzyme 2 (ACE2) as the binding site to enter the host cell in tongue, bronchi, and lungs. Any condition enhancing the expression of ACE2 would increase the vulnerability to infection. Heart failure, coronary artery disease, hypertension, diabetes, ACE inhibitors (ACEi), or angiotensin receptor blockers (ARBs) increase the expression of ACE2, which can be considered nature's endogenous ACEi at the cellular level.